Choosing your best route to DTx commercialization
In this guide, Castor discusses routes to digital therapeutics commercialization and tools to meet the challenges on the path to market
Navigating the DTx regulatory landscape
The regulations around digital therapeutics (DTx) are constantly changing. Learn how DTx providers are trying to overcome these challenges
Today’s challenges for digital therapeutics
Digital Therapeutics (DTx) is a rapidly growing space whose players are facing challenges in scaling their businesses, including testing. Learn more about growing successfully.
Regulating digital therapeutic cybersecurity: today and tomorrow
Cybersecurity has become a concern for Digital Therapeutics (DTx) developers and regulatory bodies. Learn to balance functionality & security.
Capturing and Managing Data in DTx Trials
Download this whitepaper to gain a comprehensive overview of DTx, its regulatory landscape, and routes to commercialization.
Digital Therapeutic Cybersecurity: Know Your Data Flow
A robust digital therapeutics cybersecurity system is integral to protecting users’ sensitive information helps meet regulatory requirements and maintain public trust.
Digital Therapeutic Cybersecurity: Keeping Participant Data Safe
DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.
Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.
Castor Leads Next-Gen Clinical Trials that Support Digital Therapeutics
Castor’s new eConsent platform will improve remote patient recruitment and enrollment as well as access to diverse populations by decentralizing clinical trials.